Statistical methodology Statistical analyses on the data for fibroblasts obtained from nifedipine (seven strains) reactive patients on the means of 3-5 multiple experiments were carried out by the multiple analysis of variance (multiple ANOVA) and the significance was established on the basis of the NewmanKeuls test at P < 0.05.
Results

Homogeneity
of fibroblasts Each group of cell-strains used in the present experiment were subjected to flow cytometry and were each found to give homogeneous samples in terms of the appearance of SC-F (difference of size and characteristics of cell surface) and SC-S (difference of inner substance) .
Cell proliferation
The effect of calcium-channel blockers and phenytoin on relative growth rates (number of cells in experiment /number of cells in non-drug-treated control) in nifedipine, nicardipine, and nisoldipine responders are summarized in Fig. 1 . With all calcium-channel blockers and phenytoin , fibroblasts from subjects reactive to nifedipine showed better growth than ones reactive to nicardipine and nisoldipine. Fibroblasts from subjects reactive to nicardipine showed better growth by nifedipine and those reactive to nisoldipine by nicardipine and phenytoin . All fibroblasts from subjects reactive to calcium-channel blockers showed better growth with all calcium-channel blockers and phenytoin than non-drug-treated controls (the relative growth rate was greater than 1). No statistical difference was found among the calcium-channel blockers in the subjects reactive to nifedipine.
DNA synthesis
The effect of calcium-channel blockers and phenytoin on relative [3H]-thymidine incorporation rates (radioactivity in experiment/radioactivity in non-drug-treated control) are summarized in Fig. 2 . With all calcium-channel blockers and phenytoin, except for nicardipine in fibroblasts from nifedipine-reactive patients, all fibroblasts from subjects reactive to calcium-channel blockers showed greater [3H]-thymidine incorporation than non-drug-treated controls (the relative [3H]-thymidine incorporation rate was greater than 1). No statistical difference was found among the calcium-channel blockers in the subjects reactive to nifedipine. Collagen synthesis The effects of calcium-channel blockers and phenytoin on the relative [31-1]-proline incorporation rate (radioactivity in experiment/radioactivity in non-drug-treated control) in the collagenase digestible collagen are shown in Fig. 3 .
With most calcium-channel blockers and phenytoin, fibroblasts from subjects reactive to nifedipine showed less collagen synthesis than non-drug-treated controls (the relative [31-1]-proline incorporation rate was smaller than 1). Only phenytoin treatment on fibroblasts reactive to nifedipine and nisoldipine gave greater collagen synthesis. No statistical difference was found among the calciumchannel blockers in the subjects reactive to nifedipine.
Assay for EGF
The effects of calcium-channel blockers and phenytoin on relative number of the high affinity EGF receptors (Bmax 1) and the low affinity EGF receptors (Bmax2) (number in experiment/number in non-drug-treated control) are summarized in Fig. 4 . With all calcium-channel blockers and phenytoin, fibroblasts from subjects reactive to nifedipine and nicardipine had greater relative numbers of Bmaxi (Fig. 4A) . Only with verapamil and phenytoin, fibroblasts from subjects reactive to nisoldipine showed greater relative numbers of Bmax1. In case of Bmax2, fibroblasts from subjects reactive to nifedipine and nicardipine showed greater relative numbers of Bmax2 (Fig. 4B) . Only with nifedipine and verapamil, fibroblasts from subject reactive to nisoldipine showed a greater relative number of Bmax2. Thus, both fibroblasts from subjects reactive to nifedipine and nicardipine were affected to increase the number of Bmax1 and Bmax2 by calciumchannel blockers and phenytoin.
The effects of calcium-channel blockers and phenytoin on relative affinities of high and low affinity EGF receptors (Kd1 and Kd2, respectively) (Kd of experimental/Kd of non-A Fig. 3 drug-treated control) are summarized in Fig. 5 . Most of relativeKdis in fibroblasts from subjects reactive to nifedipine, nicardipine, and nisoldipine showed smaller relativeKd1, except in the one from subjects reactive to nisoldipine, for nifedipine and nicardipine showed greater relativeKd1 (Fig. 5A ). All Kd2s in fibroblasts from subjects reactive to nifedipine were greater than those of non-drugtreated controls (Fig. 5B) . No statistical differences were found among the calcium-channel blockers in the subjects reactive to nifedipine in Bmax and Kd values. Discussion This is our first and a rare case of gingival overgrowth found in a patient receiving nisoldipine (22) . At present, only one case was found out of 76 nisoldipine-receiving patients. Since nifedipine, nicardipine, and nisoldipine are all dihydropyridine calcium-channel blockers (Fig .  6) , it wasofinterest to investigate the influence of calciumchannel blockers (nifedipine, diltiazem, verapamil, and nicardipine) and phenytoin on fibroblasts from patients reactive to nifedipine, nicardipine, and nisoldipine in order to find cross reactivity. Fibroblasts from subjects reactive to nifedipine and nicardipine showed almost the same trend to calcium-channel blockers and phenytoin in terms ofincreased proliferation rate and DNA synthesis . However, fibroblasts from the subject reactive to nisoldipine showed a different pattern. As suggested previously , with calciumchannel blockers and phenytoin , fibroblasts from patients reactive to nifedipine medication gave better cell proliferation rates and DNA synthesis than ones from non-reactive patients (17) . The same trend was found in fibroblasts from patients reactive to nicardipine medication, but not in fibroblasts from the patient reactive to nisoldipine. Thus, nifedipine and nicardipine might act in quite a similar manner to gingival fibroblasts obtained from patients reactive to nifedipine or nicardipine medication. The statistical analysis of the data for fibroblasts obtained from the nisoldipine-reactive patient was not performed in the present study because of the limitation of number of strains available.
Nishikawa etal. (23) reported that both responder and non-responder cells to nifedipine were not significantly sensitive to EGF on DNA synthesis as compared to the control cells. We demonstrated in this investigation that responder cells to nifedipine and nicardipine gave an increasing number of cell-surface EGF receptors when they were treated with calcium-channel blockers and phenytoin than those of non-drug-treated controls. Although we did not compare fibroblasts from reactive and non-reactive patients, the treatment with all calcium-channel blockers or phenytoin enhanced reactivity to EGF in fibroblasts from reactive patients.
Modeer and Andersson (20) reported that phenytoin regulated EGF receptor metabolism in human gingival fibroblasts by increasing the number of cell-surface EGF receptors which might contribute to the alteration of gingival connective tissue observed in patients undergoing phenytoin medication.Modeer et al. (21) also reported that in fibroblasts derived from a patient who developed gingival overgrowth during phenytoin medication (responder) as well as in the fibroblasts derived from a patient where gingival overgrowth did not develop (non-responder), the affinity of the EGF receptor for EGF was not significantly changed. However, phenytoin medication resulted in a down-regulation of EGF receptor metabolism in fibroblasts derived from a responder patient, whereas in the nonresponder patient EGF receptor metabolism was upregulated. In case of nifedipine and nicardipine, the number of EGF receptors was increased in fibroblasts from patients reactive to nifedipine and nicardipine with calcium-channel blockers and phenytoin. The present data support the former explanation that suggests an increase in EGF receptors. Since the relative Bmax was generally greater than 1 (the ratio of drug treated/non-drug-treated was greater than 1) in the present study, it was not likely that calcium-channel blockers cause down-regulation in fibroblasts obtained from reactive patients. The relative Kdis in fibroblasts from subjects reactive to nifedipine, nicardipine and nisoldipine were generally smaller then those of non-drug-treated controls. On the contrary, Kd2s in fibroblasts from subjects reactive to nifedipine were greater than those of non-drug-treated controls. This indicates the presence of two different kinds of EGF receptors on negative cooperativity. Although the nature of EGF receptor was not clarified in the present study, the further study might be necessary to clarify it. These findings suggest that fibroblasts obtained from subjects reactive to a specific calcium-channel blocker showed cross-reactivity to the other calcium-channel blockers. Thus, care should be taken when one changes from one calcium-channel blocker to another.
